Although there is evidence for a reduction in new-onset arrhythmic events in patients treated with SGLT2-i, previous studies yielded inconclusive results and a variable association between SGLT2-i treatment and cardiac arrhythmias (22–24). The gene discussed is SLC5A2; the disease is chronic obstructive pulmonary disease.